No Data
No Data
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A document of the tenth batch of national procurement reporting catalog has circulated within the industry. Today, when the reporter verified with the relevant department, they indicated that it is an internal document not for public release, and the formal joint procurement document will be released publicly later. ②Several industry experts have provided feedback to the reporter, stating that this reporting catalog does not represent the final procurement catalog. However, the competitive landscape of the tenth batch of national procurement will involve at least seven companies. ③The competition for the tenth batch of national procurement will be exceptionally fierce.
What happened during the National Day holiday at home and abroad? Here is a summary of important financial news.
①Shanghai Stock Exchange: From October 8th, the acceptance time for designated trading order instructions will be extended; Goldman Sachs has raised the Chinese stock market to "overweight", expecting a further increase of 15-20%; ②Hong Kong stocks are booming with a high increase in the number of new brokerage accounts and margin trading data within the past week; Many places have introduced optimized policies for real estate, and the market has responded positively.
Another wave! The revised version of the "Biosecurity Act" introduced to the legislative agenda in the US Senate, but the suspense of "breaking through" still lingers.
①On the 23rd local time in the United States, the U.S. Senate will include Amendment S.3558 in the Senate legislative agenda by general order, confirming the new name of the bill, and there is unusual movement in the BrightGene system; ②Amendment S.3558 does not include the "grandfather clause" of the House version of the Biosecurity Act regarding exemptions, nor does it make any changes to the entities involved.
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
JMP Securities Initiates Coverage On BeiGene With Market Outperform Rating, Announces Price Target of $288
Beigene's stock price was hit by bearish news! It is accused of stealing trade secrets. The company denies the accusations and vows to vigorously defend itself.
①AbbVie has once again filed a lawsuit against Beigene, accusing Beigene of stealing core business secrets to develop BTK degraders. ②Previously, AbbVie sued Beigene for patent infringement of zanubrutinib (BTK inhibitor), and the case is under review. Beigene stated that this has not had a negative impact on the research and sales of zanubrutinib in the United States.